Skip to main navigation
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
  • Careers
  • Contact Us
  • Policies
BOLSTER Trial FORTIFIDE Trial
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Advanced Solid Tumors Certepetide (LSTA1)
  • Research & Technology
    • Overview
    • CendR Platform® Technology – Targeted penetration technology to enhance drug delivery to advanced solid tumors
    • CD34+ Cell Technology
      • Coronary Microvascular Dysfunction (CMD) XOWNA®
      • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
      • Diabetic Kidney Disease (DKD) LSTA201
      • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
      • CD34+ Cell Technology Publications
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financials & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management
      • Board of Directors
    • Historical Information
      • Historical Press Releases
      • Historical SEC Filings
    • Investor Resources
      • Stockholder Information
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Policies & Disclosures
  • Patients & Families
    • Overview
    • Cholangiocarcinoma (Bile Duct Cancer) Signs, Symptoms and Treatment
    • Metastatic Pancreatic Ductal Adenocarcinoma Symptoms, Signs & Treatment
  • Clinical Trials
Investors & News / IR Contact /

IR Contact

  • Print Page
  • RSS Feeds
  • Email Alerts
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Advanced Solid Tumors Certepetide (LSTA1)
  • Research & Technology
    • Overview
    • CendR Platform® Technology – Targeted penetration technology to enhance drug delivery to advanced solid tumors
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
    • Financials & Filings
    • Stock Information
    • Corporate Governance
    • Historical Information
    • Investor Resources
  • Patients & Families
    • Overview
    • Cholangiocarcinoma (Bile Duct Cancer) Signs, Symptoms and Treatment
    • Metastatic Pancreatic Ductal Adenocarcinoma Symptoms, Signs & Treatment
  • Clinical Trials
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

© 2024 Lisata Therapeutics, Inc. All rights reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100